Lust auf Rezept?

Übersicht:

Sexuelle Störungen bei Frauen sind im klinischen Alltag ein häufiges Problem. Bisher stehen jedoch nur wenige Medikamente zur Behandlung dieser Probleme zur Verfügung. Hauptziel der Forschung ist heute die Entwicklung von Medikamenten, mit deren Hilfe das bei Frauen im Vordergrund stehende Problem einer Libidostörung gebessert werden könnte. Im Fokus des Interesses stehen dabei einerseits Sexualsteroide, andererseits zentral wirksame Substanzen. Eine konventionelle systemische und/oder lokale Östrogenbehandlung kann in der Postmenopause helfen, östrogenmangelbedingte vulvovaginale Probleme zu behandeln und die sexuelle Funktion wiederherzustellen. Oft reicht eine solche Therapie allein nicht aus. Neuere Studien zeigen, dass Androgene als unabhängige Faktoren für Libido, sexuelle Aktivität und sexuelle Zufriedenheit von großer Bedeutung sind. Es liegen überzeugende Daten vor, dass Frauen mit einem eindeutigen Androgenmangel, z. B. infolge einer beidseitigen Adnexektomie, von einer Testosterontherapie profitieren. Dies gilt auch für Frauen, die auf natürlichem Weg in die Wechseljahre gekommen sind. Zurzeit gibt es noch keine belastbare wissenschaftliche Grundlage für eine systemische Therapie sexueller Funktionsstörungen mit dem Nebennierenrindenhormon Dehydroepiandrosteron (DHEA). Vielversprechend sind jedoch erste Studien zum lokalen Einsatz von DHEA bei vaginalen Atrophiesymptomen. Seit einigen Jahren wird auch intensiv daran geforscht, zentralwirksame Substanzen zu entwickeln, die positive Effekte auf die Sexualfunktion bei Frauen haben könnten. Dazu gehören u. a. Substanzen, die den Serotonin- Noradrenalin- und Dopaminstoffwechsel beeinflussen können. 

Schlüsselwörter:

Apomorphin - Bupropion - DHEAS - Flibanserin - Melanocortin-Agonisten - Östrogen - PDE-V-Inhibitor - Testosteron - Tibolon

Literatur

• 1 Arlt W, Callies F, van Vlijmen J C, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte H M, Allolio B. Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency.  New Engl J Med. 1999;  341 1013-1020
• 2 Archer J S, Love-Geffen T E, Herbst-Damm K L, Swinney D A, Chang J R. Effect of Estradiol versus Estradiol and Testosterone on Brain-Activation Patterns in Postmenopausal Women.  Menopause. 2006;  13 528-537
• 3 Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, Goldstein I, Guay A, Leiblum S, Lobo R, Notelovitz M, Rosen R, Sarrel P, Sherwin B, Simon J, Simpson E, Shifren J, Spark R, Traish A. Female Androgen Insufficiency: The Princeton Consensus Statement on Definition, Classification, and Assessment.  Fertil Steril. 2002;  77 660-665
• 4 Basson R, Brotto L A. Sexual Psychophysiology and Effects of Sildenafil Citrate in Oestrogenised Women with Acquired Genital Arousal Disorder and Impaired Orgasm: a Randomised Controlled Trial.  BJOG. 2003;  110 1014-1024
• 5 Basson R, Brotto L A, Petkau J, Labrie F. Role of Androgens in Women’s Sexual Dysfunction.  Menopause. 2010;  17 962-971
• 6 Basson R, McInnes R, Smith M D, Hodgson G, Koppiker N. Efficacy and Safety of Sildenafil Citrate in Women with Sexual Dysfunction Associated with Female Sexual Arousal Disorder.  J Womens Health Gend Based Med. 2002;  11 367-377
• 7 Barnhart K T, Freeman E, Grisso J A, Rader D J, Sammel M, Kapoor S, Nestler J E. The Effect of Dehydroepiandrosterone Supplementation to Symptomatic Perimenopausal Women on Serum Endocrine Profiles, Lipid Parameters, and Health-Related Quality of Life.  J Clin Endocrinol Metab. 1999;  84 3896-3902
• 8 Baulieu E E, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, Faucounau V, Girard L, Hervy M P, Latour F, Leaud M C, Mokrane A, Pitti-Ferrandi H, Trivalle C, de Lacharrière O, Nouveau S, Rakoto-Arison B, Souberbielle J C, Raison J, Le Bouc Y, Raynaud A, Girerd X, Forette F. Dehydroepiandrosterone (DHEA), DHEA Sulfate, and Aging: Contribution of the DHEAge Study to a Sociobiomedical Issue.  Proc Natl Acad Sci USA. 2000;  97 4279-4284
• 9 Bechara A, Bertolino M V, Casabé A, Fredotovich N. A Double-Blind Randomized Placebo Control Study Comparing the Objective and Subjective Changes in Female Sexual Response Using Sublingual Apomorphine.  J Sex Med. 2004;  1 209-214
• 10 Berman J R, Berman L A, Toler S M, Gill J, Haughie S. Sildenafil Study Group . Safety and Efficacy of Sildenafil Citrate for the Treatment of Female Sexual Arousal Disorder: a Double-Blind, Placebo Controlled Study.  J Urol. 2003;  170 2333-2338
• 11 Bitzer J, Kenemans P, Mueck A O. FSDeducation Group . Breast Cancer Risk in Postmenopausal Women Using Testosterone in Combination with Hormone Replacement Therapy.  Maturitas. 2008;  59 209-218
• 12 Borsini F, Ceci A, Bietti G, Donetti A. BIMT 17, a 5-HT1A Receptor Agonist / 5-HT2A Receptor Antagonist, Directly Activates Postsynaptic 5-HT Inhibitory Responses in the Rat Cerebral Cortex.  Naunyn Schmiedebergs Arch Pharmacol. 1995;  352 283-290
• 13 Borsini F, Cesana R. Mechanism of Action of Flibanserin in the Learned Helplessness Paradigm in Rats.  Eur J Pharmacol. 2001;  433 81-89
• 14 Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S. Pharmacology of Flibanserin.  CNS Drug Rev. 2002;  8 117-142
• 15 Brown D A, Kyle J A, Ferrill M J. Assessing the Clinical Efficacy of Sildenafil for the Treatment of Female Sexual Dysfunction.  Ann Pharmacother. 2009;  43 1275-1285
• 16 Burger H G, Dudley E C, Cui J, Dennerstein L, Hopper J L. A Prospective Longitudinal Study of ­Serum Testosterone, Dehydroepiandrosterone Sulfate, and Sex Hormone-Binding Globulin Levels through the Menopause Transition.  J Clin Endocrinol Metab. 2000;  85 2832-2838
• 17 Cavalcanti A L, Bagnoli V R, Fonseca A M, Pastore R A, Cardoso E B, Paixão J S, Soares  Jr J M, Saad F, Baracat E C. Effect of Sildenafil on Clitoral Blood Flow and Sexual Response in Postmenopausal Women with Orgasmic Dysfunction.  Int J Gynecol Obstet. 2008;  102 115-119
• 18 Caruso S, Agnello C, Intelisano G, Farina M, Di Mari L, Cianci A. Placebo-Controlled Study on ­Efficacy and Safety of Daily Apomorphine SL Intake in Premenopausal Women Affected by Hypoactive Sexual Desire Disorder and Sexual Arousal Disorder.  Urology. 2004;  63 955-959
• 19 Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal Women Affected by Sexual Arousal Disorder Treated with Sildenafil: a Double-Blind, Cross-Over, Placebo-Controlled Study.  BJOG. 2001;  108 623-628
• 20 Caruso S, Rugolo S, Mirabella D, Intelisano G, Di Mari L, Cianci A. Changes in Clitoral Blood Flow in Premenopausal Women Affected by Type 1 Diabetes after Single 100-mg Administration of Sildenafil.  Urology. 2006;  68 161-165
• 21 Clayton A H, Croft H A, Horrigan J P, Wightman D S, Krishen A, Richard N E, Modell J G. Bupropion Extended Release Compared with Escitalopram: Effects on Sexual Functioning and Anti­depressant Efficacy in 2 Randomized, Double-Blind, Placebo-Controlled Studies.  J Clin Psychiatry. 2006;  67 736-746
• 22 Crenshaw T L, Goldberg J P, Stern W C. Pharmacologic Modification of Psychosexual Dysfunction.  J Sex Marital Ther. 1987;  13 239-252
• 23 Davis S R, Davison S L, Donath S, Bell R J. Circulating Androgen Levels and Self-Reported Sexual Function in Women.  JAMA. 2005;  294 91-96
• 24 Davis S R, Papalia M A, Norman R J, O’Neill S, Redelman M, Williamson M, Stuckey B G, Wlodarczyk J, Gardner K, Humberstone A. Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal Women: a Randomized Trial.  Ann Intern Med. 2008;  148 569-577
• 25 Davison S L, Bell R, Donath S, Montalto J G, Davis S R. Androgen Levels in Adult Females: Changes with Age, Menopause, and Oophorectomy.  J Clin Endocrinol Metab. 2005;  90 3847-3853
• 26 Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive Sexual Desire Disorder in Menopausal Women: a Survey of Western European Women.  J Sex Med. 2006;  3 212-222
• 27 Diamond L E, Earle D C, Heiman J R, Rosen R C, Perelman M A, Harning R. An Effect of the Subjec­tive Sexual Response in Premenopausal Women With Sexual Arousal Disorder by Bremelanotide (PT-141), a Melanocortin Receptor Agonist.  J Sex Med. 2006;  3 628-638
• 28 Fogle R H, Stanczyk F Z, Zhang X, Paulson R J. Ovarian Androgen Production in Postmenopausal Women.  J Clin Endocrinol Metab. 2007;  92 3040-3043
• 29 Goldstat R, Briganti E, Tran J, Wolfe R, Davis S R. Transdermal Testosterone Therapy Improves Well-Being, Mood, and Sexual Function in Premenopausal Women.  Menopause. 2003;  10 390-398
• 30 Graziottin A. Prevalence and Evaluation of Sexual Health Problems – HSDD in Europe.  J Sex Med. 2007;  4 Suppl 3 211-219
• 31 Guay A, Munarriz R, Jacobson J, Talakoub L, Traish A, Quirk F, Goldstein I, Spark R. Serum Androgen Levels in Healthy Premenopausal Women with and Without Sexual Dysfunction: Part A. Serum Androgen Levels in Women Aged 20–49 Years with No Complaints of Sexual Dysfunction.  Int J Impot Res. 2004;  16 112-120
• 32 Guay A, Jacobson J, Munarriz R, Traish A, Talakoub L, Quirk F, Goldstein I, Spark R. Serum Androgen Levels in Healthy Premenopausal Women With and Without Sexual Dysfunction: Part B: Reduced Serum Androgen Levels in Healthy Premenopausal Women with Complaints of Sexual Dysfunction.  Int J Impot Res. 2004;  16 121-129
• 33 Hackbert L, Heiman J. Acute Dehydroepiandrosterone (DHEA) Effects on Sexual Arousal in Postmenopausal Women.  J Womens Health Gend Based Med. 2002;  11 155-162
• 34 Hadley M E. Discovery That a Melanocortin Regulates Sexual Functions in Male and Female Humans.  Peptides. 2005;  26 1687-1689
• 35 Hunt P J, Gurnell E M, Huppert F A, Richards C, Prevost A T, Wass J A, Herbert J, Chatterjee V K. Improvement in Mood and Fatigue after Dehydroepiandrosterone Replacement in Addison’s Disease in a Randomized, Double Blind Trial.  J Clin Endocrinol Metab. 2000;  85 4650-4656
• 36 Jolly E, Clayton A H, Thorp J, Nappi R, Kimura T, Sand M, Pyke R. Daten präsentiert auf dem ­Annual Meeting of the International Society for the Study of Women’s Sexual Health. St. Petersburg, USA; 2010
• 37 Judd H L, Lucas W E, Yen S SC. Effect of Oophorectomy on Circulating Testosterone and Androstenedione Levels in Patients with Endometrial Cancer.  Am J Obstet Gynecol. 1974;  118 793-798
• 38 Kaplan S A, Reis R B, Kohn I J, Ikeguchi E F, Laor E, Te A E, Martins A C. Safety and Efficacy of Sildenafil in Postmenopausal Women with Sexual Dysfunction.  Urology. 1999;  53 481-686
• 39 Kingsberg S, Shifren J, Wekselman K, Rodenberg C, Koochaki P, DeRogatis L. Evaluation of the Clin­ical Relevance of Benefits Associated with Transdermal Testosterone Treatment in ­Postmenopausal Women with Hypoactive Sexual Desire Disorder.  J Sex Med. 2007;  4 1001-1008
• 40 Laan E, van Lunsen H W, Evaraerd W. The Effects of Tibolone on Vaginal Blood Flow, Sexual ­Desire and Arousablilty in Postmenopausal Women.  Climacteric. 2001;  4 28-41
• 41 Labrie F. DHEA, Important Source of Sex Steroids in Men and Even More in Women.  Prog Brain Res. 2010;  182 97-148
• 42 Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez J L, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Bérubé R, Bélanger P, Berger L, Gilbert L, Martel C, Balser J. Serum Steroid Levels During 12-Week Intravaginal Dehydroepiandrosterone Ad­ministration.  Menopause. 2009;  16 897-906
• 43 Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez J L, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal Dehydroepiandrosterone (Prasterone), a Physiological and Highly Efficient Treatment of ­Vaginal Atrophy.  Menopause. 2009;  16 907-922
• 44 Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez J L, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Effect of ­Intravaginal Dehydroepiandrosterone (Prasterone) on Libido and Sexual Dysfunction in Postmenopausal Women.  Menopause. 2009;  16 923-931
• 45 Labrie F, Bélanger A, Cusan L, Gomez J L, Candas B. Marked Decline in Serum Concentrations of Adrenal C19 Sex Steroid Precursors and Conjugated Androgen Metabolites During Aging.  J Clin Endocrinol Metab. 1997;  82 2396-2402
• 46 Laughlin G A, Barrett-Connor E, Kritz-Silverstein D, von Mühlen D. Hysterectomy, Oophorec­tomy, and Endogenous Sex Hormone Levels in Older Women: the Rancho Bernardo Study.  J Clin Endocrinol Metab. 2000;  85 645-651
• 47 Laumann E O, Nicolosi A, Glasser D B GSSAB Investigators’ Group et al.,. Sexual Problems Among Women and Men Aged 40–80 y: Prevalence and Correlates Identified in the Global Study of Sexual Attitudes and Behaviors.  Int J Impot Res. 2005;  17 39-57
• 48 Mathias C, Cardeal Mendes C M, Ponde’ de Sena E, Dias de Moraes E, Bastos C, Braghiroli M I, ­Nunez G, Athanazio R, Alban L, Moore H CF, del Giglio A. An Open-Label, Fixed-Dose Study of Bupropion Effect on Sexual Function Scores in Women Treated for Breast Cancer.  Annals of Oncology. 2006;  17 1792-1796
• 49 Moynihan R. The Making of a Disease: Female Sexual Dysfunction.  BMJ. 2003;  326 45-47
• 50 Moynihan R. Merging of Marketing and Medical Science: Female Sexual Dysfunction.  BMJ. 2010;  341 c5050
• 51 Nathorst-Böös J, Hammar M. Effect on Sexual Life – a Comparison Between Tibolone and a Continuous Estradiol–Norethisterone Acetate Regimen.  Maturitas. 1997;  26 15-20
• 52 Nijland E A, Weijmar Schultz W C, Nathorst-Boös J, Helmond F A, Van Lunsen R H, Palacios S, Norman R J, Mulder R J, Davis S R LISA study investigators. Tibolone and Transdermal E2 / NETA for the Treatment of Female Sexual Dysfunction in Naturally Menopausal Women: Results of a Randomized Active-Controlled Trial.  J Sex Med. 2008;  5 646-656
• 53 Nurnberg H G, Hensley P L, Heiman J R, Croft H A, Debattista C, Paine S. Sildenafil Treatment of Women with Antidepressant-Associated Sexual Dysfunction: a Randomized Controlled Trial.  JAMA. 2008;  300 395-404
• 54 Panjari M, Bell R J, Jane F, Wolfe R, Adams J, Morrow C, Davis S R. A Randomized Trial of Oral DHEA Treatment for Sexual Function, Well-Being, and Menopausal Symptoms in Postmenopausal Women with Low Libido.  J Sex Med. 2009;  6 2579-2590
• 55 Pfaus J G. Pathways of Sexual Desire.  J Sex Med. 2009;  6 1506-1533
• 56 Pluchino N, Ninni F, Stomati M, Freschi L, Casarosa E, Valentino V, Luisi S, Genazzani A D, Potì E, Genazzani A R. One-Year Therapy with 10 mg / day DHEA Alone or in Combination with HRT in Postmenopausal Women: Effects on Hormonal Milieu.  Maturitas. 2008;  59 293-303
• 57 Safarinejad M R. Reversal of SSRI-Induced Female Sexual Dysfunction by Adjunctive Bupropion in Menstruating Women: Double-Blind, Placebo-Controlled and Randomized Study.  J Psychopharmacol. 2010;  [Epub ahead of print]
• 58 Safarinejad M R, Hosseini S Y, Asgari M A, Dadkhah F, Taghva A. A Randomized, Double-Blind, ­Placebo-Controlled Study of the Efficacy and Safety of Bupropion for Treating Hypoactive ­Sexual Desire Disorder in Ovulating Women.  BJU Int. 2010;  106 832-839
• 59 Santoro N, Torrens J, Crawford S, Allsworth J E, Finkelstein J S, Gold E B, Korenman S, Lasley W L, Luborsky J L, McConnell D, Sowers M F, Weiss G. Correlates of Circulating Androgens in Mid-Life Women: the Study of Women’s Health Across the Nation.  J Clin Endocrinol Metab. 2005;  90 4836-4845
• 60 Schweitzer I, Maguire K, Ng C. Sexual Side-Effects of Contemporary Antidepressants: Review.  Aust N Z J Psychiatry. 2009;  43 795-808
• 61 Schwenkhagen A, Studd J. Role of Testosterone in the Treatment of Hypoactive Sexual Desire Disorder.  Maturitas. 2009;  63 152-159
• 62 Segraves R T, Clayton A, Croft H, Wolf A, Warnock J. Bupropion Sustained Release for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women.  J Clin Psychopharmacol. 2004;  24 339-342
• 63 Segraves R T, Croft H, Kavoussi R, Ascher J A, Batey S R, Foster V J, Bolden-Watson C, Metz A. Bupropion Sustained Release (SR) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Nondepressed Women.  J Sex Marital Ther. 2001;  27 303-316
• 64 Serretti A, Chiesa A. Treatment-Emergent Sexual Dysfunction Related to Antidepressants: a Meta-Analysis.  J Clin Psychopharmacol. 2009;  29 259-266
• 65 Sherwin B B, Gelfand M M. The Role of Androgen in the Maintenance of Sexual Functioning in Oophorectomized Women.  Psychosom Med. 1987;  49 397-409
• 66 Shifren J L, Braunstein G D, Simon J A, Casson P R, Buster J E, Redmond G P, Burki R E, Ginsburg E S, Rosen R C, Leiblum S R, Caramelli K E, Mazer N A. Transdermal Testosterone Treatment in ­Women with Impaired Sexual Function After Oophorectomy.  N Engl J Med. 2000;  343 682-688
• 67 Shifren J L, Davis S R, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, Bearnson P, Kakos N, O’Neill S, Levine S, Wekselman K, Buch A, Rodenberg C, Kroll R. Testosterone Patch for the Treatment of Hypoactive Sexual Desire Disorder in Naturally Menopausal Women: Results from the INTIMATE NM1 Study.  Menopause. 2006;  13 770-779
• 68 Shifren J L, Monz B U, Russo P A, Segreti A, Johannes C B. Sexual Problems and Distress in United States Women: Prevalence and Correlates.  Obstet Gynecol. 2008;  112 970-978
• 69 Somboonporn W, Davis S, Seif M W, Bell R. Testosterone for Peri- and Postmenopausal Women. Cochrane Database Syst Rev 2005 4 CD004509
• 70 Turna B, Apaydin E, Semerci B, Altay B, Cikili N, Nazli O. Women With Low Libido: Correlation of Decreased Androgen Levels with Female Sexual Function Index.  Int J Impot Res. 2005;  17 148-153
• 71 West S L, D’Aloisio A A, Agans R P, Kalsbeek W D, Borisov N N, Thorp J M. Prevalence of Low desire and Hypoactive Sexual Desire Disorder in a Nationally Representative Sample of US Women.  Arch Intern Med. 2008;  168 1441-1449
• 72 Ziaei S, Moghasemi M, Faghihzadeh S. Comparative Effects of Conventional Hormone Replacement Therapy and Tibolone on Climacteric Symptoms and Sexual Dysfunction in Postmenopausal Women.  Climacteric. 2010;  13 147-156
• 73 Zumoff B, Strain G W, Miller L K, Rosner W. Twenty-Four-Hour Mean Plasma Testosterone Concentration Declines With Age in Normal Premenopausal Women.  J Clin Endocrinol Metab. 1995;  80 1429-1430